Results 141 to 150 of about 46,872 (214)

SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration. [PDF]

Endocrinol Metab (Seoul)
Noh SW, Ryu HS, Kim YH, Oh BC.
europepmc   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study. [PDF]

Diabetes Obes Metab
Azegami T, Kaneko H, Okada A, Suzuki Y, Ko T, Aoyama K, Nakayama T, Kimura Y, Fujiu K, Takeda N, Morita H, Yokoo T, Node K, Nangaku M, Takeda N, Yasunaga H, Hayashi K.   +16 more
europepmc   +1 more source

Trends in Healthcare Costs in Heart Failure and Its Clinical Phenotypes During the Implementation of SGLT2 Inhibitors: A Finnish Registry Study. [PDF]

Clinicoecon Outcomes Res
Hansen JL, Tarkia M, Vasilevska M, Sandin P, Asllanaj E, Wammes K, Mesterton J, Airaksinen KEJ.   +7 more
europepmc   +1 more source

Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications. [PDF]

Pharmaceutics
Koo N, Lee EJ, Chang JE, Lee KR, Chae YJ.   +4 more
europepmc   +1 more source

Real-world effectiveness of SGLT2 inhibitors in patients with HF and ESKD: a multicenter cohort study. [PDF]

Front Cardiovasc Med
Wu JY, Tseng KJ, Kao CL, Hung KC, Yu T, Lin YM.   +5 more
europepmc   +1 more source

SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors and the risk of hypomagnesemia in type 2 diabetes: A target trial emulation. [PDF]

PLoS Med
Shao SC, Tsai DH, Chuang AT, Liu KH, Lai EC.   +4 more
europepmc   +1 more source

SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art. [PDF]

Clin Kidney J
Minutolo R, Ruotolo C, Conte G, Borrelli S.   +3 more
europepmc   +1 more source

SGLT2 independent effects of the SGLT2 inhibitor empagliflozin

This thesis explores how sodium glucose cotransporter 2 inhibitors (SGLT2i), particularly empagliflozin (EMPA), reduce cardiovascular risk by investigating their effects on cardiac infarction, hypertrophy, and heart failure (HF). SGLT2i demonstrate significant cardiovascular benefits across diabetic and non-diabetic populations, possibly through off ...
openaire   +2 more sources

Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Kumari K, Bai A, Geeta F, Wadhwani N, Kumar R, Kumar A, Kumari R, Bai L, Muskan F, Kashish F, Yousafzai M.   +10 more
europepmc   +1 more source